Global Proliferative Vitreoretinopathy Market Insights, Size and Growth Forecast To 2027

Published: Nov 2020	Report ID: HLCA2044	Pages: 1 - 250	Formats^*:
Category : Healthcare

The Global Proliferative Vitreoretinopathy market will fuel the market demand owing to surgical treatment and the old age population. The Global Proliferative Vitreoretinopathy market will bolster the CAGR in the forecast period from 2020-2027. The increasing geriatric population, increasing surgical treatment, common diseases like cataracts seen in old age people, improving medical technology, and treatment are fueling the market demand for the global Proliferative Vitreoretinopathy market.

Proliferative vitreoretinopathy is commonly known as blinding eye disease caused by abnormal repair of damaged vitreous and retina. PVR is the main reason for the failure of the surgery for rhegmatogenous retinal detachment.

The pathogenesis is the retinal detachment caused contraction and traction of the extensive fibroproliferative membrane on the surface of the retina and behind the vitreous. Fibrous proliferation membrane is mainly composed of pigment epithelial cells, glial cells, fibroblasts, fibroblasts, and macrophages. Pigment epithelial cells play an essential role in the occurrence and development of proliferative vitreoretinopathy.

Drug Type Overview in the Global Proliferative Vitreoretinopathy Market

Based on drug type, the global Proliferative Vitreoretinopathy market distributed into PRM-167, XOMA-089, Others. The XOMA-089 segment holds a significant share in the global proliferative vitreoretinopathy market. XOMA 089 is a novel, fully human monoclonal antibody that specifically binds and neutralizes TGF-beta 1 and 2 ligands. XOMA 089 reduced the clinical stage and severity of PVR and retinal detachment and formation of the intraocular membrane in a shorter period.

End-use Overview in the Global Proliferative Vitreoretinopathy Market

Based on end-use, the global Proliferative Vitreoretinopathy market distributed into Hospitals, Clinics, Ambulatory Surgical Centers, Others. The hospital segment has dominated the demand for the global proliferative vitreoretinopathy market. The hospitals have a higher requirement of drugs like PRM-167, XOMA-089, and others for an emergency. Moreover, various surgeries also take place in hospitals of cataracts and other diseases. Thus, propelling the market share of the proliferative vitreoretinopathy in the global market.

Region Overview in the Global Proliferative Vitreoretinopathy Market

Based on geography, the global gases and equipment market segmented into North America, Europe, Asia Pacific, South America, and Middle East & Africa. North America is the fastest-growing region for the proliferative vitreoretinopathy market. It is mainly due to the region's rapid economic growth and some vast technological development. The prevalence of the geriatric population, emerging cases of cataracts, and the rapid development of new drugs are fueling the market demand for the proliferative vitreoretinopathy in North America.

Global Proliferative Vitreoretinopathy Market: Competitive Landscape

Companies such as Novartis AG, Promedior, Inc., RXi Pharmaceuticals Corp., Allergan plc, Regeneron Pharmaceuticals, Inc., Genentech, Inc., among others, are key players in the global Proliferative Vitreoretinopathy market.

1. Research Strategic Development

1.1. Market Modelling
1.2. Product Analysis
1.3. Market Trend and Economic Factors Analysis
1.4. Market Segmental Analysis
1.5. Geographical Mapping
1.6. Country Wise Segregation

2. Research Methodology

2.1. Identification of Target Market
2.2. Data Acquisition
2.3. Refining of Data/ Data Transformations
2.4. Data Validation through Primary Techniques
2.5. Exploratory Data Analysis
2.6. Graphical Techniques/Analysis
2.7. Quantitative Techniques/Analysis
2.8. Visual Result/Presentation

3. Executive Summary

4. Market Insights

4.1. Economic Factor Analysis
4.1.1. Drivers
4.1.2. Trends
4.1.3. Opportunities
4.1.4. Challenges
4.2. Competitors & Product Analysis
4.3. Regulatory Framework
4.4. Company market share analysis, 2019
4.5. Porter’s Five forces analysis
4.6. New Investment Analysis
4.7. PESTEL Analysis

5. Global Proliferative Vitreoretinopathy Market Overview

5.1. Market Size & Forecast, 2016-2027
5.1.1. Demand
5.1.1.1. By Value (USD Million)
5.2. Market Share & Forecast, 2016-2027
5.2.1. By Drug Type
5.2.1.1. PRM-167
5.2.1.2. XOMA-089
5.2.1.3. Others
5.2.2. By End-user
5.2.2.1. Hospitals
5.2.2.2. Clinics
5.2.2.3. Ambulatory Surgical Centers
5.2.2.4. Others
5.2.3. By Region
5.2.3.1. Europe
5.2.3.2. North America
5.2.3.3. Asia Pacific
5.2.3.4. South America
5.2.3.5. Middle East & Africa

6. Europe Proliferative Vitreoretinopathy Market Overview

6.1. Europe Proliferative Vitreoretinopathy Size & Forecast, 2016-2027
6.1.1. Demand
6.1.1.1. By Value (USD Million)
6.2. Europe Proliferative Vitreoretinopathy Market Share & Forecast, 2016-2027
6.2.1. By Drug Type
6.2.1.1. PRM-167
6.2.1.2. XOMA-089
6.2.1.3. Others
6.2.2. By End-user
6.2.2.1. Hospitals
6.2.2.2. Clinics
6.2.2.3. Ambulatory Surgical Centers
6.2.2.4. Others
6.2.3. By Country
6.2.3.1. Germany
6.2.3.2. UK
6.2.3.3. France
6.2.3.4. Italy
6.2.3.5. Rest of Europe
6.2.4. Company Market Share (Top 3-5)
6.2.5. Economic Impact Study on Europe Proliferative Vitreoretinopathy Market

7. North America Proliferative Vitreoretinopathy Market Overview

7.1. North America Proliferative Vitreoretinopathy Market Size & Forecast, 2016-2027
7.1.1. Demand
7.1.1.1. By Value (USD Million)
7.2. North America Proliferative Vitreoretinopathy Market Share & Forecast, 2016-2027
7.2.1. By Drug Type
7.2.1.1. PRM-167
7.2.1.2. XOMA-089
7.2.1.3. Others
7.2.2. By End-user
7.2.2.1. Hospitals
7.2.2.2. Clinics
7.2.2.3. Ambulatory Surgical Centers
7.2.2.4. Others
7.2.3. By Country
7.2.3.1. US
7.2.3.2. Canada
7.2.3.3. Mexico
7.2.4. Company Market Share (Top 3-5)
7.2.5. Economic Impact Study on North America Proliferative Vitreoretinopathy Market

8. Asia Pacific Proliferative Vitreoretinopathy Overview

8.1. Asia Pacific Proliferative Vitreoretinopathy Market Size & Forecast, 2016-2027
8.1.1. Demand
8.1.1.1. By Value (USD Million)
8.2. Asia Pacific Proliferative Vitreoretinopathy Market Share & Forecast, 2016-2027
8.2.1. By Drug Type
8.2.1.1. PRM-167
8.2.1.2. XOMA-089
8.2.1.3. Others
8.2.2. By End-user
8.2.2.1. Hospitals
8.2.2.2. Clinics
8.2.2.3. Ambulatory Surgical Centers
8.2.2.4. Others
8.2.3. By Country
8.2.3.1. China
8.2.3.2. India
8.2.3.3. Japan
8.2.3.4. Australia
8.2.3.5. Rest of Asia Pacific
8.2.4. Company Market Share (Top 3-5)
8.2.5. Economic Impact Study on Asia Pacific Proliferative Vitreoretinopathy Market

9. South America Proliferative Vitreoretinopathy Market Overview

9.1. South America Proliferative Vitreoretinopathy Market Size & Forecast, 2016-2027
9.1.1. Demand
9.1.1.1. By Value (USD Million)
9.2. South America Proliferative Vitreoretinopathy Market Share & Forecast, 2016-2027
9.2.1. By Drug Type
9.2.1.1. PRM-167
9.2.1.2. XOMA-089
9.2.1.3. Others
9.2.2. By End-user
9.2.2.1. Hospitals
9.2.2.2. Clinics
9.2.2.3. Ambulatory Surgical Centers
9.2.2.4. Others
9.2.3. By Country
9.2.3.1. Brazil
9.2.3.2. Argentina
9.2.3.3. Rest of South America
9.2.4. Company Market Share (Top 3-5)
9.2.5. Economic Impact Study on South America Proliferative Vitreoretinopathy Market

10. Middle East & Africa Proliferative Vitreoretinopathy Market Overview

10.1. Middle East & Africa Proliferative Vitreoretinopathy Market Size & Forecast, 2016-2027
10.1.1. Demand
10.1.1.1. By Value (USD Million)
10.2. Middle East & Africa Proliferative Vitreoretinopathy Market Share & Forecast, 2016-2027
10.2.1. By Drug Type
10.2.1.1. PRM-167
10.2.1.2. XOMA-089
10.2.1.3. Others
10.2.2. By End-user
10.2.2.1. Hospitals
10.2.2.2. Clinics
10.2.2.3. Ambulatory Surgical Centers
10.2.2.4. Others
10.2.3. By Country
10.2.3.1. Saudi Arabia
10.2.3.2. UAE
10.2.3.3. South Africa
10.2.3.4. Rest of Middle East & Africa
10.2.4. Company Market Share (Top 3-5)
10.2.5. Economic Impact Study on Middle East & Africa Proliferative Vitreoretinopathy Market

11. Competitor Analysis

11.1. Company Description
11.2. Financial Analysis
11.3. Key Products
11.4. Key Management Personnel
11.5. Contact Address
11.6. SWOT Analysis
11.7. Company Profile
11.7.1.1. Novartis AG
11.7.1.2. Promedior, Inc.
11.7.1.3. RXi Pharmaceuticals Corp.
11.7.1.4. Allergan plc
11.7.1.5. Regeneron Pharmaceuticals, Inc.
11.7.1.6. Genentech, Inc.
11.7.1.7. Other players.

SPER Market Research’s methodology uses great emphasis on primary research to ensure that the market intelligence insights are up to date, reliable and accurate. Primary interviews are done with players involved in each phase of a supply chain to analyze the market forecasting. The secondary research method is used to help you fully understand how the future markets and the spending patterns look likes.

The report is based on in-depth qualitative and quantitative analysis of the Product Market. The quantitative analysis involves the application of various projection and sampling techniques. The qualitative analysis involves primary interviews, surveys, and vendor briefings. The data gathered as a result of these processes are validated through experts opinion. Our research methodology entails an ideal mixture of primary and secondary initiatives.

SPER-Methodology-1